Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma

Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma | ReachRx